HUMA
Q4 2026 EPS Estimate
$-0.09
Nov 6, 2026 · Reports before open
Revenue Estimate
$1M
FY2029E EPS$0.10
FY2030E EPS$0.30

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
73
Score
10 Buy (91%)1 Hold (9%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1091%
Hold
19%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$2.00
+263.6%
Consensus
$2.00
+263.6%
Bull
$2.00
+263.6%
12-Month Target Range11 analysts
$2.00$2.00$2.00
Current $0.55Consensus
Current Price
$0.55
Upside to Consensus
$1.45

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+313.95%
EPS
FY2028
Rev+353.54%
EPS
FY2029
Rev+94.39%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$6M$26M$119M$232M$343M
Low$6M$17M$54M$118M$175M
High$7M$36M$200M$385M$568M
EBITDA Avg$1M$5M$24M$46M$69M
Low$1M$3M$11M$24M$35M
High$1M$7M$40M$77M$114M
EBIT Avg$-1M$-5M$-24M$-46M$-69M
Low$-1M$-7M$-40M$-77M$-114M
High$-1M$-3M$-11M$-24M$-35M
Net Income Avg$-55M$-39M$-17M$15M$47M
Low$-59M$-42M$-23M$5M$17M
High$-51M$-36M$18M$28M$88M
EPS Avg$-0.34$-0.25$-0.03$0.10$0.30
Low$-0.37$-0.27$-0.14$0.03$0.11
High$-0.32$-0.23$0.11$0.18$0.56
Analysts (Rev / EPS)4 / 34 / 35 / 42 / 12 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$2M$3M$3M$4M$8M$11M$34M$42M
Low$2M$2M$2M$3M$6M$8M$26M$32M
High$3M$3M$4M$5M$10M$14M$43M$53M
EBITDA Avg$436,279$514,879$584,999$835,839$2M$2M$7M$8M
Low$370,837$389,145$442,142$631,727$1M$2M$5M$6M
High$500,043$641,928$729,351$1M$2M$3M$9M$11M
EBIT Avg$-436,279$-514,879$-584,999$-835,839$-2M$-2M$-7M$-8M
Low$-500,043$-641,928$-729,351$-1M$-2M$-3M$-9M$-11M
High$-370,837$-389,145$-442,142$-631,727$-1M$-2M$-5M$-6M
Net Income Avg$-21M$-20M$-19M$-18M$-16M$-14M$866,474$4M
Low$-24M$-27M$-25M$-24M$-21M$-18M$591,401$3M
High$-18M$-14M$-13M$-12M$-11M$-9M$1M$6M
EPS Avg$-0.09$-0.09$-0.08$-0.08$-0.07$-0.06$0.00$0.02
Low$-0.10$-0.11$-0.11$-0.10$-0.09$-0.08$0.00$0.01
High$-0.08$-0.06$-0.05$-0.05$-0.05$-0.04$0.00$0.02
Analysts (Rev / EPS)3 / 21 / 11 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026BTIG
BTIG Reiterates Buy Rating on Humacyte (HUMA)
Target:$2.00
+213.6%from $0.64
Dec 1, 2025H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Humacyte (HUMA)
Target:$3.00
+122.2%from $1.35
Oct 13, 2025UBS
Humacyte price target lowered to $6 from $7 at BTIG
Target:$6.00
+256.9%from $1.68
Aug 27, 2025Barclays
Humacyte initiated with an Overweight at Barclays
Target:$3.50
+138.1%from $1.47
Oct 18, 2024Piper Sandler
Piper Sandler Reiterates Neutral Rating on Humacyte (HUMA)
Target:$6.00
+23.5%from $4.86
Oct 18, 2024BTIG
BTIG Reiterates Buy Rating on Humacyte (HUMA)
Target:$10.00
+105.8%from $4.86
Dec 20, 2022Cowen & Co.
Humacyte (HUMA) Stock Gets A $5 Price Target
Target:$5.00
+126.5%from $2.21
May 15, 2022Piper Sandler
Humacyte downgraded to Underweight from Overweight at Piper Sandler
Target:$4.00
-25.5%from $5.37
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.